119 related articles for article (PubMed ID: 37313647)
1. Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US.
Song X; Chen CI; Konidaris G; Zimmerman NM; Ruiz E
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):911-920. PubMed ID: 37313647
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.
Cowey CL; Robert NJ; Espirito JL; Davies K; Frytak J; Lowy I; Fury MG
Cancer Med; 2020 Oct; 9(20):7381-7387. PubMed ID: 32578965
[TBL] [Abstract][Full Text] [Related]
3. Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Chapalain M; Baroudjian B; Dupont A; Lhote R; Lambert J; Bagot M; Lebbe C; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1202-1209. PubMed ID: 31587382
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature.
Jarkowski A; Hare R; Loud P; Skitzki JJ; Kane JM; May KS; Zeitouni NC; Nestico J; Vona KL; Groman A; Khushalani NI
Am J Clin Oncol; 2016 Dec; 39(6):545-548. PubMed ID: 24879468
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma.
Vo TT; Espirito JL; Boyd M; Gumuscu B; Chirovsky D; Robert NJ; Swaby RF; Zhou W; Cowey CL
Future Oncol; 2022 Jun; 18(17):2087-2099. PubMed ID: 35240857
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
Kearney M; Thokagevistk K; Boutmy E; Bharmal M
J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
[TBL] [Abstract][Full Text] [Related]
7. Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.
Venables ZC; Autier P; Nijsten T; Wong KF; Langan SM; Rous B; Broggio J; Harwood C; Henson K; Proby CM; Rashbass J; Leigh IM
JAMA Dermatol; 2019 Mar; 155(3):298-306. PubMed ID: 30484823
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
9. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
10. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review.
Trodello C; Pepper JP; Wong M; Wysong A
Dermatol Surg; 2017 Jan; 43(1):40-49. PubMed ID: 27618393
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
[TBL] [Abstract][Full Text] [Related]
14. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
[TBL] [Abstract][Full Text] [Related]
15. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
16. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cetuximab in the treatment of squamous cell carcinoma.
Preneau S; Rio E; Brocard A; Peuvrel L; Nguyen JM; Quéreux G; Dreno B
J Dermatolog Treat; 2014 Oct; 25(5):424-7. PubMed ID: 23167307
[TBL] [Abstract][Full Text] [Related]
18. Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States.
Lukowiak TM; Aizman L; Perz A; Miller CJ; Sobanko JF; Shin TM; Giordano CN; Higgins HW; Etzkorn JR
JAMA Dermatol; 2020 Nov; 156(11):1192-1198. PubMed ID: 32845319
[TBL] [Abstract][Full Text] [Related]
19. Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone.
Ben-Joseph R; Bell JA; Chitnis A; Kansal A; Holly P; Paramore C; Wild H
J Med Econ; 2016; 19(2):169-80. PubMed ID: 26451633
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.
Dereure O; Missan H; Girard C; Costes V; Guillot B
Dermatology; 2016; 232(6):721-730. PubMed ID: 28384639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
